Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Salomon Manier

Showing results (31-40 of 151) with videos related to

Pageof 16
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 11, 2012
Mechanisms of activity of the TORC1 inhibitor everolimus in Waldenstrom macroglobulinemiaAldo M Roccaro, Antonio Sacco, Xiaojing Jia, et al.
Frontiers in Oncology|January 29, 2019
Deregulation and Targeting of TP53 Pathway in Multiple MyelomaKatarina K Jovanović, Guillaume Escure, Jordane Demonchy, et al.
Experimental Hematology|June 15, 2024
Key role of glutamine metabolism in persistence of leukemic cells upon exposition to FLT3 tyrosine kinase inhibitorsRaeeka Khamari, Claire Degand, Quentin Fovez, et al.
Blood Reviews|February 1, 2015
The cancer glycome: carbohydrates as mediators of metastasisSiobhan V Glavey, Daisy Huynh, Michaela R Reagan, et al.
Clinical Lymphoma, Myeloma & Leukemia|April 2, 2011
High-throughput genomic analysis in Waldenström's macroglobulinemiaStéphanie Poulain, Esteban Braggio, Christophe Roumier, et al.
Leukemia & Lymphoma|October 21, 2021
Smoldering multiple myeloma: biology, clinical manifestations and managementLaly Nsiala, Arthur Bobin, Anthony Levy, et al.
Blood Advances|April 4, 2019
Citron Rho-interacting kinase silencing causes cytokinesis failure and reduces tumor growth in multiple myelomaIlyas Sahin, Yawara Kawano, Romanos Sklavenitis-Pistofidis, et al.
Clinical Lymphoma, Myeloma & Leukemia|July 4, 2026
Real-World Evidence of Immunotherapy Sequencing in Multiple Myeloma: Durable Responses With BCMA-Targeting Bispecific Antibodies Following Prior GPRC5D-Targeting TherapyTitouan Cazaubiel, Cyrille Touzeau, Laure Vincent, et al.
BMC Cancer|April 29, 2024
Progression-free survival as a surrogate endpoint for overall survival in patients with relapsed or refractory multiple myelomaMeletios Dimopoulos, Pieter Sonneveld, Salomon Manier, et al.
American Journal of Hematology|July 26, 2014
Targeting survival and cell trafficking in multiple myeloma and Waldenstrom macroglobulinemia using pan-class I PI3K inhibitor, buparlisibIlyas Sahin, Feda Azab, Yuji Mishima, et al.
Pageof 16

Showing results (31-40 of 151) with videos related to

Sort By:
Pageof 16
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 11, 2012
Mechanisms of activity of the TORC1 inhibitor everolimus in Waldenstrom macroglobulinemiaAldo M Roccaro, Antonio Sacco, Xiaojing Jia, et al.
Frontiers in Oncology|January 29, 2019
Deregulation and Targeting of TP53 Pathway in Multiple MyelomaKatarina K Jovanović, Guillaume Escure, Jordane Demonchy, et al.
Experimental Hematology|June 15, 2024
Key role of glutamine metabolism in persistence of leukemic cells upon exposition to FLT3 tyrosine kinase inhibitorsRaeeka Khamari, Claire Degand, Quentin Fovez, et al.
Blood Reviews|February 1, 2015
The cancer glycome: carbohydrates as mediators of metastasisSiobhan V Glavey, Daisy Huynh, Michaela R Reagan, et al.
Clinical Lymphoma, Myeloma & Leukemia|April 2, 2011
High-throughput genomic analysis in Waldenström's macroglobulinemiaStéphanie Poulain, Esteban Braggio, Christophe Roumier, et al.
Leukemia & Lymphoma|October 21, 2021
Smoldering multiple myeloma: biology, clinical manifestations and managementLaly Nsiala, Arthur Bobin, Anthony Levy, et al.
Blood Advances|April 4, 2019
Citron Rho-interacting kinase silencing causes cytokinesis failure and reduces tumor growth in multiple myelomaIlyas Sahin, Yawara Kawano, Romanos Sklavenitis-Pistofidis, et al.
Clinical Lymphoma, Myeloma & Leukemia|July 4, 2026
Real-World Evidence of Immunotherapy Sequencing in Multiple Myeloma: Durable Responses With BCMA-Targeting Bispecific Antibodies Following Prior GPRC5D-Targeting TherapyTitouan Cazaubiel, Cyrille Touzeau, Laure Vincent, et al.
BMC Cancer|April 29, 2024
Progression-free survival as a surrogate endpoint for overall survival in patients with relapsed or refractory multiple myelomaMeletios Dimopoulos, Pieter Sonneveld, Salomon Manier, et al.
American Journal of Hematology|July 26, 2014
Targeting survival and cell trafficking in multiple myeloma and Waldenstrom macroglobulinemia using pan-class I PI3K inhibitor, buparlisibIlyas Sahin, Feda Azab, Yuji Mishima, et al.
Pageof 16